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Objectives: Functional characterization of a mutant Candida albicans drug resistance protein (Cdr1p)
by overexpression in Saccharomyces cerevisiae.
Methods: We overexpressed green fluorescent protein-tagged Cdr1p in S. cerevisiae AD1-8u2 host and
introduced a point mutation to substitute T1351 with F in Cdr1p. The cells expressing T1351F mutant
Cdr1p were analysed for their functional activity using minimum inhibitory concentration, spot assay,
and fluconazole efflux. The binding activity of photoaffinity analogues 8-azidoATP, iodoarylazidoprazo-
sin and azidopine to the mutant T1351F Cdr1p was also characterized.
Results: The T1351F mutant Cdr1p-expressing cells were susceptible to anisomycin, cycloheximide,
fluconazole, miconazole and nystatin. The mutant protein was expressed to the same level as that of
native Cdr1p in S. cerevisiae cells and was properly localized to the cell surface. There was also no
difference between the mutant variant and the native protein’s ability to bind a photoaffinity analogue
of ATP, 8-azidoATP, or the radiolabelled photoaffinity agents iodoarylazidoprazosin and azidopine.
However, the substitution of T1351 resulted in considerable reduction in its ability to export fluor-
escent substrate rhodamine 6G. The synergy between calcineurin inhibitors FK520 and azoles was
abrogated in cells expressing the T1351F mutant variant of Cdr1p.
Conclusions: The results from this study suggest that the T1351 in the predicted transmembrane
domain (TMD) 11 of Cdr1p is not only important for drug-substrate transport but also has a role in gov-
erning synergy of FK520.
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Introduction
Candida albicans is a fungal pathogen which is responsible for
opportunistic infections in immunocompromised patients.
Several drugs are used to treat candidiasis and most target the
ergosterol biosynthetic pathway or its final product, ergosterol, a
cell membrane component that is unique to fungi. The most com-
monly used drugs in both the treatment and prevention of candi-
diasis are azoles.1 – 3 Azoles are fungistatic rather than fungicidal
to Candida cells. As a result, this tolerance to azoles contributes to
the development of the resistance sometimes encountered in
clinical isolates from immunocompromised patients.2 – 5
A number of mechanisms contribute to the development of
azole resistance in C. albicans.6 – 10 One of these is the energy-
dependent drug efflux which results from an overexpression of
genes encoding drug efflux pump proteins belonging to the
ATP-binding cassette (ABC) as well as the major facilitators
(MFS) superfamilies of transporters.7,11 – 13 Among ABC transpor-
ters, CDR1 and CDR2 are major efflux pumps, whose over-
expression plays a key role in azole resistance in C. albicans.
Thus, invariably, transcript levels of CDR1 and CDR2 genes are
elevated in azole-resistant clinical isolates recovered from
patients receiving long-term antifungal therapy.9,10 In many cases,
the up-regulation of CDR1 results in decreased intracellular
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levels of fluconazole thus corroborating its direct involvement in
drug efflux.14,15
The molecular mechanisms which govern the function of
Cdr1p or Cdr2p as efflux pumps for azoles are not well known
and information is needed (1) to understand how the protein can
bind a structurally diverse range of compounds including differ-
ent azoles, (2) to define the drug–substrate binding, and (3) to
determine how ATP binding and hydrolysis are linked to drug
transport. In an effort to develop an understanding of the mole-
cular details of drug binding and transport, recently, we overex-
pressed Cdr1p as a green fluorescent protein (GFP)-tagged
fusion protein in a heterologous hyper-expression system of
Saccharomyces cerevisiae. Based on conserved residues among
various drug transporters, we had generated several mutant var-
iants of Cdr1p.16 We observed that several point mutations
resulted in mutant variants of Cdr1p, which were susceptible to
different drugs.16 In this study, we chose a mutant T1351F
(where a threonine 1351 of TM11 was replaced by phenyl-
alanine), for functional characterization as it showed suscept-
ibility to antifungal agents. Of note, T1351 is a conserved
residue of TM11 of many drug transporters wherein either a
threonine or a serine is present and has been implicated in drug
susceptibility.17,18 We show that the mutant T1351F Cdr1p was
properly expressed and localized to the cell surface, exhibited
similar binding of the ATP and photoaffinity analogues of drugs
and had no difference in ATPase activity. However, the cells
expressing the mutant protein were hypersusceptible to all the
tested drugs. Additionally, the known synergy between azoles
and calcineurin inhibitors was abrogated in mutant variant
T1351F.19 – 22 Our results for the first time demonstrate a direct
involvement of Cdr1p in synergy between immunosuppressant
analogue FK520 and azoles.
Materials and methods
Anti-GFP monoclonal antibody was purchased from BD Biosciences
Clontech, Palo Alto, CA, USA. DNA modifying enzymes were
purchased from Roche Molecular Biochemicals, Germany. Prot-
ease inhibitors, miconazole, ketoconazole, nystatin, cycloheximide,
anisomycin, rhodamine 6G and other molecular grade chemicals
were obtained from Sigma Chemical Co (St. Louis, MO, USA). The
radiolabelled [125I]IAAP (Iodoarylazidoprazosin) (2200 Ci/mmol)
was from Perkin–Elmer Life Sciences (Boston, MA, USA),
[a-32P]8-azidoATP (15–20 Ci/mmol) from Affinity Labeling Tech-
nologies, Inc. (Lexington, KY, USA), [3H]fluconazole (20 Ci/mmol)
and [3H]azidopine (60 Ci/mmol) from Amersham Biosciences
(Arlington Heights, IL, USA). The [a-32P]8-azidoATP showed no
detectable contaminating [a-32P]8-azidoADP by thin-layer chroma-
tography with 0.8 M LiCl as the solvent. Fluconazole was kindly
provided by Ranbaxy Laboratories, India. FK520 was a generous
gift from Merck & Co., Inc., Rahway, USA.
Bacterial and yeast strains and growth media
Plasmids were maintained in Escherichia coli XL-1 blue.
Escherichia coli was cultured in Luria-Bertani medium (Difco, BD
Biosciences, NJ, USA) to which ampicillin was added (100 mg/L).
The S. cerevisiae strain used was AD1-8u (Mat a, pdr1-3, his1,
ura3, Dyor1::hisG, Dsnq 2::hisG, Dpdr5::hisG, Dpdr10::hisG,
Dpdr11::hisG, Dycf1::hisG, Dpdr3::hisG, Dpdr15::hisG) (provided
by Professor Richard D. Cannon, University of Otago, Dunedin,
New Zealand). PSCDR1-GFP and T1351F were AD1-8u deriva-
tives expressing Cdr1p-GFP and its mutant protein (mutant Cdr1p-
GFP), respectively. The yeast strains were cultured in Yeast Extract
Peptone Dextrose (YEPD) broth (Bio101, Vista CA, USA). For agar
plates, 2% (w/v) Bacto agar (Difco, BD Biosciences, NJ, USA) was
added to the medium.
Site-specific mutagenesis and development of transformants
Site-directed mutagenesis was carried out by use of the Quick-
Change Mutagenesis system from Stratagene (La Jolla, CA, USA).
The mutation was introduced into plasmid pPSCDR1-GFP,16 accord-
ing to manufacturer’s instructions and the desired nucleotide
sequence alteration was confirmed by DNA sequencing of the ORF.
The mutated pPSCDR1-GFP after linearizing with XbaI was used to
transform AD1-8u cells as described previously.16
Preparation of purified plasma membranes
of S. cerevisiae cells
Crude membranes were prepared from S. cerevisiae cells grown in
YEPD to late exponential phase. The protease inhibitor cocktail
(1 mM PMSF, 1 mg/L leupeptin, pepstatin A and aprotinin) was
added to the culture and the cells were harvested. The cells were
broken with glass beads by vortexing the cells four times for 30 s
followed by a 30 s interval on ice. The homogenization medium
contained 50 mM Tris pH 7.5 and 2.5 mM EDTA and the protease
inhibitor cocktail. The lysate was centrifuged at 1000 g to remove
unbroken cells and the crude membranes were pelleted by ultra-
centrifugation of low speed supernatant at 100 000 g for 1 h. Finally,
the crude membranes were suspended in suspension buffer (10 mM
Tris pH 7.5, 0.5 mM EDTA and 10% glycerol). The crude mem-
brane suspension was applied to a discontinuous gradient made of
an equal volume of 53.5% (w/v) sucrose and 43.5% (w/v) sucrose.
After centrifugation for 5 h at 100 000 g in a Beckman SW 28 rotor,
the purified plasma membranes were recovered at 43.5/53.5 inter-
face as described by Monk et al.23
Immunodetection of Cdr1p in plasma membrane
The western blot analysis was done with anti-Cdr1p polyclonal anti-
body (1:500 dilution) or anti-GFP monoclonal antibody (1:1000
dilution), anti-Pma1p polyclonal antibody (1:10 000 dilution) as
described previously.16
Drug susceptibility and other functional parameters
of S. cerevisiae
The susceptibilities of S. cerevisiae cells to different drugs were
determined by microdilution and spot assays as described earlier.24
The Cdr1p-associated ATPase activity of the purified plasma mem-
brane was measured as oligomycin-sensitive release of inorganic
phosphate as described previously.16 Efflux of rhodamine 6G and
the accumulation of [3H]fluconazole were determined essentially by
protocols as described previously.24,25
Photoaffinity labelling with [125I]IAAP, [3H]azidopine,
[a-32P]8-azidoATP
The plasma membrane (15mg) protein was photoaffinity labelled
with 3–6 nM [125I]IAAP (2200 Ci/mmol) or 0.5mM [3H]azidopine
(60 Ci/mmol) or with 10mM [a-32P]8-azidoATP (10mCi/nmol) and
competed with drugs as described previously.16
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Results
For functional characterization of Cdr1p, we have previously
used a hyper-expression system, where Cdr1p was stably over-
expressed from a genomic PDR5 locus in a S. cerevisiae
mutant AD1-8u.16 The AD1-8u was derived from a Pdr1-3
mutant strain with a gain of function mutation in the transcrip-
tion factor Pdr1p, resulting in a constitutive hyperinduction
of the PDR5 promoter.11 We tagged the GFP gene at the
C-terminal end of CDR1, which was overexpressed as a fusion
protein in PSCDR1-GFP strain and demonstrated that GFP tag-
ging and overexpression did not impair functional activity of
the protein.16 To dissect molecular details of drug binding and
transport mediated by Cdr1p, site-directed mutagenesis was
employed to generate several mutant variants.16 The following
study pertains to one such mutant variant of Cdr1p where
threonine 1351 of TMD11 is substituted by phenylalanine
(T1351F).
Drug resistance profile of T1351F mutant Cdr1p-GFP
The mutation T1351F was introduced in the overexpressing
Cdr1p-GFP plasmid (pPSCDR1-GFP).16 The mutated plasmid
was integrated in S. cerevisiae (AD1-8u) as described pre-
viously.16 Southern hybridization confirmed that the gene was
inserted as a single copy at the genomic PDR5 locus (data not
shown). Two positive clones of the mutant were selected to rule
out clonal variations. Confirmed positive mutants were screened
for their sensitivity to drugs by two independent methods,
by MIC80 determination and by spot assay. As depicted in
Figure 1(a and b), the T1351F mutant cells became susceptible
to anisomycin, cycloheximide, fluconazole, miconazole and nys-
tatin compared to native Cdr1p-GFP. In the following experi-
ments, we analysed some functional parameters to ascertain the
phenotype of T1351F.
T1351F was properly expressed and localized
at the cell surface
To explore if the observed changes in drug susceptibilities of
T1351F mutant Cdr1p-GFP were due to alterations in protein
functions rather than due to altered expression levels, we did a
fluorescence activated cell sorting (FACS) analysis of the live
cells which showed that the fluorescence intensity in T1351F
cells was comparable to the wild-type PSCDR1-GFP (Figure 2a).
The confocal images confirmed that the wild-type and mutant
T1351F Cdr1p-GFP was properly localized at the cell surface
(Figure 2b). The western blot of the mutant as well as the wild-
type Cdr1p-GFP plasma membrane proteins with anti-GFP mono-
clonal antibody (upper panel Figure 2c) and with anti-Cdr1p poly-
clonal antibody (middle panel Figure 2c) showed that cells with
T1351F mutant variant of Cdr1p-GFP expressed protein to the
same level as that of wild-type. These data indicate that the
observed hypersusceptibility of T1351F towards various drugs
was not due to a difference in the expression level or the localiz-
ation of mutant variant protein. Of note, the plasma membrane
(PM-ATPase) (lower panel Figure 2c) was used as a marker for
the purity and quantity of the protein in the plasma membrane
fractions.
ATPase activity, nucleotide and substrate binding of mutant
T1351F variant protein remain unchanged
We used photoaffinity analogues, 8-azidoATP (analogue of
ATP), IAAP [a photoaffinity analogue of P-glycoprotein (P-gp)
substrate, prazosin] and azidopine (a photoaffinity analogue of
dihydropyridine),16 to explore if the observed difference in drug
sensitivity was not due to any change in nucleotide or drug bind-
ing. We used a purified plasma membrane fraction from the
native and mutant variant expressing cells for photoaffinity
analogue binding and observed that there was no significant
Figure 1. Drug sensitivity of Cdr1p-GFP and T1351F expressing cells. (a) AD1-8u, PSCDR1-GFP (expressing wild-type Cdr1p) or T1351F (mutant Cdr1p-
GFP) cells were grown overnight on YEPD plates at 308C. The cells were then resuspended in normal saline to an A600 of 0.1. Five microlitres of five-fold
serial dilutions of each strain was spotted onto YEPD plates in the absence (Control) or in the presence of the following antifungal agents: anisomycin
(Aniso) (5 mg/L), cycloheximide (Cyh) (0.5 mg/L), fluconazole (Flu) (10 mg/L), miconazole (Mic) (1 mg/L) and nystatin (Nys) (1 mg/L). Growth differences
were recorded following incubation of the plates for 48 h at 308C. Growth was not affected by the presence of the solvents used for the drugs (data not
shown). (b) The drug resistance profile of AD1-8u, PSCDR1-GFP and T1351F cells. The MIC80 (mg/L) values of anisomycin (Aniso), cycloheximide (Cyh),
fluconazole (Flu), miconazole (Mic) and nystatin (Nys) for AD1-8u, PSCDR1-GFP and T1351F cells, were determined as described in Materials and
methods. The results are typical of one determination, which was confirmed by three independent experiments.
S. Shukla et al.
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difference between the specific binding of [a-32P]8-azidoATP to
the wild-type and T1351F protein (Figure 3a). It was found that
both the wild-type as well as the mutant Cdr1p-GFPs of T1351F
showed similar binding of [125I]IAAP which could be competed
out with 100mM nystatin (Figure 3b). That there was no differ-
ence in drug binding was further confirmed by examining the
binding of [3H]azidopine. It was observed that the [3H]azidopine
bound similarly to wild-type as well as mutant Cdr1p-GFP pro-
tein (Figure 3c) and could be competed out by miconazole
(100mM).
We as well as others have shown that Cdr1p elicits NBDs-
dependent oligomycin-sensitive ATPase activity.11,16 We assayed
ATPase activity in the purified plasma membrane fraction from
mutant T1351F and compared it with the wild-type Cdr1p-GFP-
expressing cells. The oligomycin-sensitive ATPase activity of
T1351F mutant (43.4 nmol Pi/min/mg) was found to be compar-
able to that of native Cdr1p-GFP (41.4 nmol Pi/min/mg). We did
not get a drug-stimulated ATPase activity with wild-type as well
as the mutant T1351F Cdr1p-GFP which would have been a cor-
rect measure of the ATPase activity contributed by the active
protein. Of note, unlike mammalian homologues of yeast ABC
drug transporters, drug-stimulated ATPase activity in any drug
transporter of yeast has not been possible to demonstrate.11,26
T1351F Cdr1p-GFP shows reduced efflux of rhodamine 6G
We used fluorescent rhodamine 6G, a known substrate of Cdr1p
to compare efflux ability of T1351F with native protein. It was
observed that T1351F mutant variant protein showed reduced
efflux of rhodamine 6G efflux (0.71 nmol/mL) compared with
Figure 3. ATP and substrate analogue binding characteristics of T1351F
mutant Cdr1p-GFP. (a) [a-32P]8-azidoATP-labelling of AD 1–8u (control),
wild-type (Cdr1p-GFP) and T1351F mutant Cdr1p-GFP. The plasma mem-
brane proteins (15mg/50mL) were photoaffinity labelled with 10mM
[a-32P]8-azidoATP (10mCi/nmol) in the absence () and presence of (+) of
10 mM ATP as described in Materials and methods. (b) [125I]IAAP labelling
of AD 1–8u (control), wild-type (Cdr1p-GFP) and T1351F mutant Cdr1p-
GFP. The plasma membrane proteins (15mg) were labelled with 3–6 nM of
[125I]IAAP (2200 Ci/mmol) as described in Materials and methods; 100mM
of nystatin (+) was added to compete with IAAP binding. (c) [3H]azidopine
labelling of AD 1–8u (control), wild-type (Cdr1p-GFP) and T1351F mutant
Cdr1p-GFP. The plasma membrane protein (30mg) was labelled with
[3H]azidopine, as described in Materials and methods, in the presence and
absence of 100mM miconazole as (+) indicated.
Figure 2. T1351F mutant Cdr1p-GFP is localized to the cell surface and
expressed to the same level as wild-type protein. (a) Flow cytometry of
S. cerevisiae AD1-8u, PSCDR1-GFP and T1351F Cdr1p-GFP cells: AD1-
8u (control), PSCDR1-GFP (Cdr1p-GFP) and T1351F cells were grown in
YEPD medium to mid log phase and used for FACS analysis in a FACSort
flow cytometer (Becton–Dickinson Immunocytometry Systems). Analysis
was carried out with CellQuest software. The histogram derived from the
CellQuest program depicts fluorescence intensity for AD1-8u, PSCDR-GFP
and T1351F cells, respectively. (b) Confocal images of S. cerevisiae cells
expressing GFP-tagged wild-type and T1351F mutant Cdr1p-GFP. Cells
were grown in YEPD medium to late log phase. The cells were washed and
resuspended in an appropriate volume of 50 mM HEPES pH 7.0. The cells
were viewed directly, on a glass slide with a drop of antifade reagent to pre-
vent photobleaching, with 100 oil emulsion objective on a Bio-Rad confo-
cal microscope (MRC 1024). (c) Expression of T1351F mutant Cdr1p-GFP
in S. cerevisiae: The plasma membrane (20mg) protein from AD1-8u
(lane 1), PSCDR1-GFP (lane 2) and T1351F (lane 3) were separated on 8%
SDS–polyacrylamide gel, electroblotted on to nitrocellulose, and incubated
with mouse monoclonal anti-GFP antibody (1:1000) (upper panel), rabbit
polyclonal anti-Cdr1p antibody (1:500 dilution) (middle panel) and rabbit
polyclonal anti-Pma1p antibody (1:10 000 dilution) (lower panel). Proteins
were immunodetected as described in Materials and methods.
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the wild-type Cdr1p-GFP-expressing cells (2.53 nmol/mL). Of
note the level of efflux by mutant variant T1351F was compar-
able to that of control AD1-8u cells (0.53 nmol/mL), which did
not express Cdr1p.
FK520 shows synergy with drugs and inhibits
Cdr1p-GFP-mediated drug resistance
In view of the known fungicidal synergic effect of the immuno-
suppressive agent tacrolimus (FK506) with azoles in
C. albicans,27 we checked the drug resistance profile of the
Cdr1p-GFP-expressing cells in presence and absence of FK520
(ascomycin), a structural analogue of FK506, to determine the
interactions between this class of compounds and azoles. In a
MIC assay, FK520 showed a MIC of 128 mg/L for PSCDR1-
GFP cells, whereas it was 16 mg/L for the control cells (data not
shown). In order to examine the reported synergy between
immunosuppressant and antifungal agents, the AD1-8u and
PSCDR1-GFP cells were grown in the presence or absence of
non-toxic concentrations of FK520 (10 mg/L) in combination
with fluconazole in a spot assay (Figure 4). It was observed that
both the cells could grow well in the presence of non-toxic con-
centration of FK520. As expected, PSCDR1-GFP cells were
resistant to fluconazole and ketoconazole compared to host AD1-
8u cells, which did not express Cdr1p. However, the resistance
to both the azoles displayed by PSCDR1-GFP cells was abro-
gated when FK520 was also included in the growth medium.
Furthermore, this synergic effect of FK520 on Cdr1p-GFP-
expressing cells was not limited to azoles since it also showed
inhibition of growth with cycloheximide (Figure 4c) and aniso-
mycin (data not shown).
The synergic effect of FK520 was further confirmed by MIC
determinations. Interestingly, the MIC of fluconazole for over-
expressing PSCDR1-GFP cells was 64 mg/L, which was reduced
to 16 mg/L in the presence of FK520 (10 mg/L) (Figure 5a).
However, under similar conditions, the addition of FK520 did
not change MIC value (1 mg/L) of fluconazole for AD1-8u
cells, which were neither expressing CDR1 nor expressing any
major efflux proteins of S. cerevisiae (Figure 5a). It is apparent
from the data that FK520 at the non-toxic concentration used
requires Cdr1p for its synergic effects. The addition of the
FK520 also did not change the MIC value (4 mg/L) of flucona-
zole for T1351F mutant Cdr1p-expressing cells suggesting the
importance of T1351 in the FK506 mediated synergy of flucona-
zole activity in Cdr1p-expressing cells (Figure 5a).
FK520 competes with fluconazole efflux
To further confirm the direct interaction of FK520 with Cdr1p
and role of T1351 in this interaction, we checked if the accumu-
lation of fluconazole could be competed out with immuno-
suppressant. For this, AD1-8u, PSCDR1-GFP and T1351F cells
were incubated with or without FK520 (10mM) with 100 nM of
[3H]fluconazole (20 Ci/mmol) and after 45 min of incubation,
samples were removed for measurement of drug accumulation.24
As shown in Figure 5(b), whereas AD1-8u cells in the absence
of FK520 accumulated 0.20 pmol of radiolabelled drug,
PSCDR1-GFP cells showed 50% less accumulation of it
(0.10 pmol). This is consistent with our model in which the
efflux activity of PSCDR1-GFP cells expressing Cdr1p prevents
accumulation of fluconazole as in control cells. Interestingly,
whereas the presence of molar excess of FK520 did not show
any significant effect on fluconazole accumulation in AD1-8u
cells, its presence increased the level of accumulation of the
drug in Cdr1p-GFP expressing cells. These results demonstrate
that FK520 can effectively compete with fluconazole and thus
could directly interact with Cdr1p. This was further verified by
the observation that the presence of a molar excess of FK520
did not have any effect on the residual fluconazole efflux ability
of the mutant T1351F Cdr1p expressing cells (Figure 5b). These
results conclusively prove that T1351 plays an important role in
the FK520-mediated synergy of fluconazole.
T1351F cells are not susceptible to inhibition by FK520
In the following experiments, a direct interaction of Cdr1p with
FK520 was again validated in the cells using the spot assay.
Since the mutant T1351F cells were susceptible to fluconazole,
we used a non-toxic concentration of it (2 mg/L) which allo-
wed the mutant T1351F cells to grow in the presence of the
drug. Under these conditions, one could see a synergy between
Figure 4. Synergy of FK520 with drugs in Cdr1p-GFP and its mutant variant
T1351F expressing cells. AD1-8u, PSCDR1-GFP and T1351F cells were
grown overnight on YEPD plates at 308C. The cells were then resuspended
in saline to an A600 of 0.1. Five microlitres of a 1:5 dilution of each strain
was spotted onto YEPD plates in the absence (growth control) or in the pre-
sence of the following drugs: (a) FK520 (10 mg/L), (b) fluconazole (2 mg/L),
(c) ketoconazole (100mg/L) and (d) cycloheximide (20mg/L) alone or in
combination as indicated. Growth differences were recorded following incu-
bation of the plates for 48 h at 308C.
S. Shukla et al.
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FK520 and antifungal agents. Cdr1p-GFP expressing cells could
not grow in non-toxic fluconazole concentration if FK520 was
also present in the medium (Figure 4). However, the presence of
the analogue FK520 prevented the drug-induced inhibition of
growth of cells expressing mutant protein (Figure 4). Thus, the
synergic ability of FK520 with drugs was severely reduced in
the mutant T1351F cells (Figure 4a and b). To ensure that the
reduced inhibitor susceptibility was because of T1351F mutation
only and was not a generalized phenomenon, we checked the
inhibitor susceptibility in another mutant, which has a mutation
of F774A in the predicted TMD6 of Cdr1p.16 Interestingly,
F774A mutant behaved like wild-type Cdr1p-GFP-expressing
cells and was susceptible to FK520 inhibition (Figure 4). Of
note, several other mutant variants of Cdr1p further confirmed
that the synergic effect of FK520 is mediated via T1351 of
Cdr1p (data not shown).
Discussion
To understand the molecular mechanism of drug transport
mediated by Cdr1p, we have recently generated several mutants
of this major efflux protein.16 In this study, we describe a mutant
variant of Cdr1p where threonine 1351 of predicted TMD11 is
replaced by phenylalanine (T1351F). We show that the T1351F
mutant variant of Cdr1p becomes susceptible to anisomycin,
cycloheximide, fluconazole, miconazole and nystatin even though
the mutant protein was properly expressed, localized to the cell
surface and displayed normal ATPase activity. The ability to
export substrates like fluorescent dye rhodamine 6G was, how-
ever, significantly reduced in cells expressing the T1351 mutant
variant protein. Thus it is very likely that the reduced efflux abil-
ity may contribute to observed enhanced drug sensitivity of
T1351F cells. Of note, the hypersusceptible variant T1351F
showed normal binding of the two photoaffinity analogues of
drug substrates and ATP. In this context, it is difficult to point
out from the available data, the reason behind reduced efflux
and hypersusceptibility of T1351F cells. In view of the similar
binding of photoaffinity analogues with T1351F protein variant,
it is likely that the release of drugs from the binding site may be
affected. A slower release of drug by T1351F protein would
result in higher accumulation and hypersusceptibility phenotype.
In a related study, Loo & Clarke28 observed that the reduced
resistance in a mutated version of human P-gp (a close homol-
ogue of Cdr1p), was accompanied by high affinity of the drug
analogue for the protein. The relative reduction in drug resist-
ance of the mutant protein was linked to the impairment of
release of the drug during the transport cycle.28
Azoles are fungistatic rather than fungicidal to Candida cells
and this tolerance to azoles contributes to the development of
resistance encountered in clinical isolates from immunocompro-
mised patients.2 – 5 Recently, it was observed that the protein
phosphatase calcineurin allows survival of C. albicans during
membrane stress exerted by azoles.29 The calcineurin inhibitors
ciclosporin A (CsA) and tacrolimus (FK506) exhibit fungicidal
synergy with azoles in C. albicans, C. glabrata, C. krusei and in
S. cervisiae.22,27 In this study, we observed that a T1351F mutant
variant of Cdr1p exhibited abrogated synergy of FK520 (a struc-
tural analogue of FK506) with fluconazole, ketoconazole and
cycloheximide. The fact that the other variants of Cdr1ps, which
have substitution mutations in different domains spanning the
entire protein molecule, remained synergically susceptible to
FK520 suggests that T1351 of predicted TMD11 specifically
contributes to this synergy. Since antifungal agents of varied
structures including azole derivatives are substrates of Cdr1p, it
is very likely that the immunosuppressants or their analogues
might increase intracellular levels of drugs by competition and
thus blocking the pump activity directly.19,21,30 The inhibition of
fluconazole efflux by FK520 suggests such a possibility of a
direct interaction of FK520 with Cdr1p (Figure 5b). That FK520
synergy is mediated at least in part by its interaction with Cdr1p
is suggested from the set of observations: 1) T1351 replacement
abrogates synergy, 2) FK520 is ineffective in cells not expres-
sing Cdr1p, 3) FK520 show synergy with other substrates of
Cdr1p, and 4) FK520 competes with fluconazole efflux.
Recently, Raymond’s group has also shown that Cdr1p can
Figure. 5. FK506 inhibitory effect is Cdr1p specific: (a) Drug susceptibility of AD1-8u, PSCDR1-GFP and T1351F cells for fluconazole, in the presence
and absence of FK520 (10 mg/L), was determined by microtitre assay.24 The graph represents OD600 nm plotted against indicated concentration of fluconazole
(filled squares, AD1-8u; open squares, AD1-8u + FK520; filled triangles, PSCDR1-GFP; open triangles, PSCDR1-GFP+FK520; filled circles, T1351F;
open circles, T1351F+FK520). (b) Effect of FK520 on fluconazole accumulation in wild-type and mutant T1351F Cdr1p-GFP-expressing cells. The accumu-
lation of fluconazole in AD1-8u, PSCDR1-GFP and T1351F cells was determined, in the presence (filled) and absence (open) of FK520 (10mM), as
described in Materials and methods. The values are given as the means±S.D. of three independent experiments.
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affect cell tolerance to FK520 and suggested a possible involve-
ment of the transporter in the synergy between azoles and
FK520 in C. albicans.31 However, Marchetti et al.32 in a report
appearing simultaneously suggested that the fungicidal synergy
of fluconazole with ciclosporin may not be dependent on the
MDR transporters of C. albicans. It should be pointed out that
Gauthier et al.31 recently observed that the Cdr1p-expressing
cells were susceptible to FK520 (50 and 70 mg/L) whereas
PSCDR1-GFP cells in this study showed resistance at similar
concentrations. This variation could be due to difference in the
level of Cdr1p activity. The Cdr1p-expressing TY310 cells in
their study showed only moderate resistance to fluconazole
(25 mg/L),31 compared to our observations (64 mg/L). Addition-
ally, different host backgrounds could also contribute to such
differences. Since azoles are actively exported by ABC transpor-
ters such as Cdr1p and Cdr2p,14,15,33 a direct inhibitory effect of
the immunosuppressants on these transporters cannot be ruled
out. In fact, Egner and colleagues17,18 have shown that the repla-
cement of S1360 of Pdr5p (homologue of Cdr1p) to phenyl-
alanine resulted in the loss of the synergy of FK506 with
fluconazole. Further if serine was changed to alanine, it resulted
in the hypersensitivity to FK506. Their observations suggested a
direct role for S1360 in mediating the synergy of fluconazole
activity with FK506 in Pdr5p. Of note, S1360 of Pdr5p is equiv-
alent to T1351 of Cdr1p in its position and location. It should be
pointed out that T1351 of Cdr1p34 was earlier predicted to be in
cytoplasmic loop 5 based on predictions described by Eisenberg
et al.35 We made a TMD prediction of Cdr1p as was done earlier
for Pdr5p sequences by PHDsec algorithm and found that both
T1351 of Cdr1p and S1360 of Pdr5p are present in TMD11.36,37
The sequence alignment of TMD11 of various ABC transporters
of C. albicans and their comparison with Pdr5p reveals that
instead of the serine residue which is present in Pdr5p, the major
drug transporters of C. albicans (Cdr1p and Cdr2p) possess
threonine (Figure 6a). When TMD11 of Cdr1p was looked at in
a helical wheel projection, it revealed an amphipathic structure
with a hydrophilic and a hydrophobic side where T1351 lies near
the boundary of the two faces of the putative helix (Figure 6b).
The importance of T1351 in the drug as well as inhibitor suscep-
tibility observed in this study is evident from its placement in
helical wheel projection wherein probably the hydrophilic face
of the helix plays a crucial role in the recognition/transport of
Cdr1p substrates. Thus it is likely that the hydrophobic face of
TMD11 could interact with the lipid layer whereas the hydrophi-
lic face may interact with other transmembrane helices or could
have direct contact with the substrate molecule. The interactivity
of the other residues of TMD11 positioned at the hydrophilic
face remains to be examined.
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